congotarget3
About
Affiliation regarding tumour mutational burden using outcomes within sufferers together with advanced sound tumours given pembrolizumab: possible biomarker investigation multicohort, open-label, phase 2 KEYNOTE-158 study.
Affiliation regarding tumour mutational burden using outcomes within sufferers together with advanced sound tumours given pembrolizumab: possible biomarker investigation multicohort, open-label, phase 2 KEYNOTE-158 study.